Biotech Stocks Fall In Reponse to Dendreon (DNDN)
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Join SI Premium – FREE
A number of biotech stocks are trading lower in sympathy with Dendreon Corp. (Nasdaq: DNDN), which is down 64% after pulling PROVENGE guidance.
InterMune Inc. (Nasdaq: ITMN) down 15%, Human Genome Sciences Inc. (Nasdaq: HGSI) down 12%, VirnetX Holding Corp (AMEX: VHC) down 4%
InterMune Inc. (Nasdaq: ITMN) down 15%, Human Genome Sciences Inc. (Nasdaq: HGSI) down 12%, VirnetX Holding Corp (AMEX: VHC) down 4%
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- New York Fed raises Q3 2026 GDP forecast to 2.3%
- Citadel has shed over 80% of aggregate risk from Situational Awareness portfolio - CNBC
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
